Medtronic touts 5-year data on InterStim neuromod device for OAB

July 17, 2017 By Brad Perriello Leave a Comment

Medtronic (NYSE:MDT) today touted 5-year results from the InSite study of its InterStim neuromodulation treatment for overactive bladder syndrome.

InterStim is designed to stimulate the sacral nerve to treat OAB, meaning urinary urge incontinence and/or urgency-frequency. The InSite study enrolled 340 patients, of which 272 were implanted with an InterStim device, comparing treatment with the device with standard drug therapy. The primary safety endpoint was to “demonstrate that the upper bound of the 95% CI for the cumulative five-year rate of adverse events related to the tined lead that require surgery is less than 33%” at 5 years, according to ClinicalTrials.gov. The primary efficacy endpoint was superior improvement in OAB symptoms at 6 months.

The study, published online in the Journal of Urology, defined therapeutic success as UI or UF improvement of at least 50% in average leaks or voids per day, or a return to normal voiding (less than 8 voids daily). Quality of life was evaluated using the International Consultation on Incontinence Modular Questionnaire. The 5-year safety outcome was the adverse event rate.

InSite showed a 5-year therapeutic success rate of 82% using a completers analysis (subjects with data at baseline and each follow-up) and 67% with a modified completers analysis (subjects who either had a baseline and follow-up evaluation or withdrew early due to device-related reasons and were considered failures). Urinary incontinence subjects had a mean reduction of 2.0 leaks per day; UF subjects showed a mean reduction of 5.4 voids per day.

“Subjects showed improvement in all QOL measures; the most common device-related adverse events were undesirable change in stimulation (22%), implant site pain (15%), and therapeutic product ineffective (13%),” according to the study. “This multicenter study shows that [sacral neuromodulation ] has sustained efficacy and QOL improvements and an acceptable safety profile through 5 years in OAB subjects.”

“Effective long-term bladder control is critical because OAB is a chronic condition that significantly impacts all aspects of a person’s quality of life, including confidence, activities and intimacy,” lead investigator Dr. Steven Siegel, of the Metro Urology Centers for Female Urology & Continence Care in Minneapolis, said in prepared remarks. “Many struggle to find long-term relief and these results, which show the InterStim system offers sustained long-term efficacy, meaningful symptom reduction and quality of life improvements, offer new hope for those who suffer.”

“The InterStim system has been an important treatment option for 20 years and is the only sacral neuromodulation treatment with five-year clinical data demonstrating sustained, long-term efficacy for the treatment of both OAB and fecal incontinence,” added pelvic health & gastric therapies VP Linnea Burman. “These data should give physicians and patients confidence that relief and restored quality of life are possible and we hope this will help encourage the many still suffering from bothersome OAB symptoms to seek help.”

NEW! Technology Track at DeviceTalks Boston

These featured panels at DeviceTalks Boston will explore the state of R&D at major medtech firms, as well as the latest trends when it comes to developing combination products, neuromodulation devices, robotic systems and women's health technology.

View Technology Track Featured Sessions

Register today to save. Use code TECHTRACK to save an additional 10%.

Study: Doctors receiving high compensation fail to disclose relationships with med device firms
Doctors aren’t accurately reporting compensation they receive from medical device companies, according to a new study published in the JAMA Surgery. In the study, researchers performed a bibliometric analysis of the 100 physicians receiving the highest compensation from 10 large surgical and medical device manufacturers using payment data from the Centers for Medicare & Medicaid […]
Vascular Graft Solutions’ aneurysm graft used in hemodialysis patients
Vascular Graft Solutions has reported the first clinical use of its Frame external support technology in high-flow arteriovenous (AV) fistulas. The first five cases were performed by Dr. Vladimir Matoussevitch from Cologne University Hospital in Germany. The braided cobalt chrome, kink-resistant external support was designed for autologous vein grafts in bypass or reconstruction of peripheral arterial […]
Murata to boost MEMS production in Finland
Murata Manufacturing announced it is investing $45 million in the purchase of two factory buildings and the construction of a third to manufacture micro electro mechanical systems (MEMS) sensors in Finland. The Kyoto-based company had been leasing the two buildings it purchased and expects to complete the adjacent 172,000-square-foot factory in Vantaa, Finland, by the end […]
This in-body GPS system could track tumor movement in real-time
Researchers from Massachusetts Institute of Technology’s Computer Science and Artificial Laboratory have developed a wireless system that acts like an in-body GPS, allowing doctors to use sensors to track tumors or dispense drugs. The system, known as the ReMix, is able to pinpoint the location of ingestible implants inside the body by using low-power wireless […]
Medical devices: The transition to connected devices
C&K Cutting Edge Blog #2 By Roger Bohannan – C&K Medical Segment Leader The shift in medical device development from the unconnected device to the connected device is upon us. This shift will make an enormous impact on the quality and effectiveness of medical care over the next decade and beyond. Device design engineers worldwide […]
ValenTx raises $10.3 million for implantable gastric bypass device
Startup ValenTx has attracted nearly $10.3 million from 32 investors, according to a filing with the Securities & Exchange Commission. The Maple Grove, Minn. company is developing a removable gastric bypass device as an alternative to Roux-en-Y gastric bypass surgery. It raised $10,271,050 in the round begun July 18, 2018. The ValenTx endoluminal bypass therapy […]
GW Plastic wins Vermont Business Growth Award and workforce development grants
GW Plastics recently announced that it has won the 2018 Vermont Business Growth Award, as well as two workforce development training grants. The annual Vermont Business Growth Award is presented by the Vermont Business Magazine and KeyBank and acknowledges the top Vermont businesses that have had the greatest growth over the last five years. This […]
FDA clears CoreLink’s new spinal implant
Spinal implant maker CoreLink has landed FDA 510(k) clearance for a new anterior lumbar (ALIF) interbody device. The Foundation 3D ALIF uses the company’s proprietary mimetic metal technology, which mimics natural bone characteristics, including 100% open-pore architecture and micro-roughened porosity with hydro-wicking properties. The new ALIF design also has patent-pending technology that creates a combination of […]
Syneo receives patent in China
Syneo recently received a patent in China for its Servo Electric Press Two-Stage Force technology. The patent gives the company the rights to use its two-stage force measuring system in manual electric press and automatic electric press (press-fit) machine applications. The patent protects the company’s technology that is featured in the two-stage force measuring system […]
FDA approves first generic Epipen
The FDA this week approved the first generic version of Mylan‘s (NSDQ:MYL) Epipen emergency allergy auto-injector. Teva Pharmaceuticals (NYSE:TEVA), which won the historic approval, plans to market the generic epinephrine auto-injector in 0.3mg and 0.15mg doses. There are other epinephrine auto-injectors on the market in the U.S., but Teva’s is the first that’s approved to directly substitute […]
FDA finalizes streamlined bundled, quarterly MDR reporting system
The FDA today announced it finalized its new Voluntary Malfunction Summary Reporting Program intended to streamline medical device manufacturer malfunction reporting. The program was created in part through public comments received by the FDA and is intended to allow manufacturers to report “certain device malfunctions in summary form on a quarterly basis” instead of an […]